ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

BI 4015092

A development code.

Its studies are led by Boehringer Ingelheim.

Furthest: phase 1, since Nov 3, 20261 company-led study, 1 open or runningNext primary completion: Nov 5, 2032 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim11 open or runningphase 1since Nov 3, 2026Nov 3, 2026Nov 5, 2032phase 1 · NCT07926334

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 3, 2026First study: phase 1 study in Advanced or Metastatic Solid Tumors With KRAS G12D MutationFirst studyNCT07926334 · 200 planned · United States, Australia, Japan and more

Ahead

  1. Nov 5, 2032Primary completion: phase 1 study in Advanced or Metastatic Solid Tumors With KRAS G12D MutationNCT07926334

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07926334Advanced or Metastatic Solid Tumors With KRAS G12D Mutation · United States, Australia, Japan and more1Not yet recruitingNov 5, 2032200

How it is read

Names in the registry

  • “BI 4015092”, 1 entry

Codes read as this program: BI4015092.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.